Neomycin

Identification

Name
Neomycin
Accession Number
DB00994
Description

Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae.5 Neomycin is a complex comprised of three components, neomycin A, B, and C.2 Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.1,2 Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together.1 Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria.9

Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units.2 Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma.5 It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear.6 Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye.7 Neomycin is also available in over-the-counter topical products to prevent minor skin infections.

Type
Small Molecule
Groups
Approved, Vet approved
Synonyms
  • Fradiomycin
  • Kaomycine
  • Neomicina
  • Neomycin
  • Vonamycin
External IDs
  • Caswell No. 595
  • USAF CB-19

Pharmacology

Indication

Oral neomycin sulfate is indicated as an adjunctive therapy in hepatic coma (portal-system encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract. It is strongly recommended that oral neomycin is only used in infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria.5

Neomycin, in combination with polymyxin B sulfates and hydrocortisone in otic suspensions, is used in the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics. This otic formulation is also used in the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.6

The ophthalmic solution containing neomycin in combination with polymyxin B sulfates and dexamethasone is used to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.7

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Neomycin mediates its bactericidal action by inhibiting bacterial protein synthesis, thereby suppressing the growth and survival of susceptible bacteria. Following oral administration, the duration of bactericidal activity of neomycin ranged from 48 to 72 hours.5 By decreasing colonic bacteria that produce ammonia, neomycin was shown to be effective as an adjunctive therapy in hepatic coma to improve neurologic symptoms.5,9

Neomycin is active against both gram positive and gram negative organisms, including the major E. coli species resident in the colon as well as the enteropathogenic forms of E. coli.9 It is also active against Klebsiella-Enterobacter group.5 Resistant strains of E. coli, Klebsiella and Proteus spp. may emerge from neomycin therapy.2 Neomycin has no antifungal activity and has some activity against some protozoa.1

Mechanism of action

Like other aminoglycoside antibiotic drugs, neomycin inhibits bacterial ribosomes by binding to the 30S ribosomal subunit of susceptible bacteria and disrupting the translational machinery of bacterial protein synthesis.3,4 Bacterial translation is normally initiated by the mRNA binding to the 30S ribosomal subunit and subsequent binding with 50S subunit for elongation.4

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
A16S ribosomal RNA
inhibitor
Enteric bacteria and other eubacteria
NExtracellular calcium-sensing receptorNot AvailableHumans
Absorption

Neomycin is poorly absorbed from the gastrointestinal tract. Gastrointestinal absorption of the drug may be increased if inflammatory or ulcerative gastrointestinal disease is present.5

Volume of distribution

The small fraction of absorbed neomycin is rapidly distributed in the tissues. The amount of systemically absorbed neomycin is reported to increase cumulatively with each repeated dose administered until a steady state is reached.5

Protein binding

Findings from protein binding studies suggest low protein binding profile for neomycin sulfate, which can range from 0-30% depending on test methods.5

Metabolism

There is limited information on the metabolism of neomycin, as there is limited systemic absorption following drug administration. Metabolism is deemed to be negligible.

Route of elimination

The small absorbed fraction of neomycin is excreted by the kidney. The unabsorbed portion of the drug is excreted unchanged in the feces.5

Half-life

There is limited information on the half-life of neomycin.

Clearance

There is limited information on the clearance rate of neomycin.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The oral LD50 of neomycin sulfate in mouse is > 8 g/kg. The subcutaneous LD50 is 200 mg/kg in rat and 190 mg/kg in mouse. The intraperitoneal LD50 in mouse is 305 mg/kg. The oral Lowest published toxic dose (TDLo) in woman is 12600 mg/kg/7D.8

Because of low absorption, acute overdosage from oral neomycin is not likely to occur. However, prolonged administration of neomycin should be avoided because of the possibility of some systemic absorption and the risk of neurotoxicity, ototoxicity, and/or nephrotoxicity. Hemodialysis will remove neomycin from the blood. While nephrotoxicity and ototoxicity have been reported in otherwise patients without compromised renal function, the risk for developing these toxicities is increased in patients with renal impairment.9 Like other aminoglycosides, neomycin may cause fetal harm and total irreversible bilateral congenital deafness when administered in pregnant women.5

Affected organisms
  • Enteric bacteria and other eubacteria
  • Pseudomonas aeruginosa
  • Haemophilus influenzae
  • Escherichia coli
  • Klebsiella
  • Enterobacter
  • Bacteroides
  • Enterobacter spp.
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirNeomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseThe metabolism of Acarbose can be decreased when combined with Neomycin.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Neomycin.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Neomycin.
AcenocoumarolThe risk or severity of bleeding can be increased when Neomycin is combined with Acenocoumarol.
AcetaminophenNeomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetophenazineNeomycin may increase the neurotoxic activities of Acetophenazine.
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Neomycin.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Neomycin is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neomycin.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Neomycin palmitate3I9J454G9F55298-68-5Not applicable
Neomycin sulfate057Y6266931405-10-3Not applicable
Product Images
International/Other Brands
Myacyne / Mycifradin / Myciguent / Neo-Rx / Neobiotic / Nivemycin
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Mycifradin Sulfate Oral SolutionSolutionOralPharmacia & Upjohn Inc1957-12-312000-08-02Canada flag
Mycifradin Sulfate Tablets 0.5 GmTabletOralPharmacia & Upjohn Inc1953-12-312000-08-02Canada flag
Myciguent OintmentOintmentTopicalUpjohn1951-12-311998-08-12Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Neo-FradinSolution87.5 mg/5mLOralX Gen Pharmaceuticals, Inc.2002-05-232012-12-31US flag
Neomycin SulfateTablet500 mg/1OralTeva Pharmaceuticals USA, Inc.1990-09-30Not applicableUS flag00093 1177 01 nlmimage10 4f2b27c9
Neomycin SulfateTablet500 mg/1OralHi-Tech Pharmacal Co. Inc.2010-03-12Not applicableUS flag50383 0565 10 nlmimage10 1f460f80
Neomycin SulfateTablet350 mg/1OralBreckenridge Pharmaceutical, Inc.2011-01-032020-04-30US flag
Neomycin SulfateTablet500 mg/1Oralbryant ranch prepack1990-09-30Not applicableUS flag
Neomycin SulfateTablet500 mg/1OralLannett Company, Inc.2016-06-10Not applicableUS flag
Neomycin SulfateTablet500 mg/1OralX-GEN Pharmaceuticals, Inc.2010-03-12Not applicableUS flag
Neomycin SulfateTablet500 mg/1OralEci Pharmaceuticals Llc2016-01-162016-07-10US flag
Neomycin SulfateTablet500 mg/1OralMajor2009-09-142012-10-01US flag
Neomycin SulfateTablet500 mg/1OralGolden State Medical Supply, Inc.2011-01-032016-03-31US flag51991 0738 01 nlmimage10 951b4ada
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AntibioticOintment3.5 mg/1gTopicalMorales Distributors, Inc.2012-09-25Not applicableUS flag
AntibioticOintment3.5 mg/1gTopicalKareway Product, Inc.2011-08-11Not applicableUS flag
AntibioticOintment3.5 mg/1gTopicalPro Mex Llc2013-12-05Not applicableUS flag
AntibioticOintment3.5 mg/1gTopicalTotal Resources International2019-10-07Not applicableUS flag
Antibiotic OintmentOintment3.5 mg/1gTopicalNeopharm Co., Ltd2010-08-26Not applicableUS flag
BaclezeneCream5 mg/0.9gTopicalCurazene, Llc2014-06-19Not applicableUS flag
Family Care AntibioticOintment3.5 mg/1gTopicalUnited Exchange Corporation2012-11-302017-12-26US flag
Family Care AntibioticOintment3.5 mg/1gTopicalUnited Exchange Corporation2017-12-29Not applicableUS flag
Family Care Triple Antibiotic Pain ReliefOintment3.5 mg/1gTopicalUnited Exchange Corporation2012-02-07Not applicableUS flag
First Aid Only Antibiotic Neomycin SulfateOintment3.5 mg/1gTopicalAcme United Corporation2017-12-18Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
10 Person ANSINeomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalGenuine First Aid2010-04-24Not applicableUS flag
25 Person ANSINeomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalGenuine First Aid2010-04-25Not applicableUS flag
4017 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4022 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4032 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4042 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4044 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4045 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4049 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g)KitTopicalHoneywell Safety Products USA, Inc2018-11-292019-10-18US flag
4050 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
4017 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4022 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4032 First Aid KitNeomycin sulfate (3.5 mg/1g) + Acetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS flag
4042 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4044 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4045 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4049 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g)KitTopicalHoneywell Safety Products USA, Inc2018-11-292019-10-18US flag
4050 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4051 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Ethanol (0.5 mL/1mL) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Lidocaine hydrochloride (20 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag
4052 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Ethanol (0.5 mL/1mL) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Lidocaine hydrochloride (20 mg/1mL)KitTopicalHoneywell Safety Products USA, Inc2018-11-212019-10-18US flag

Categories

ATC Codes
A07AA51 — Neomycin, combinationsR02AB01 — NeomycinJ01GB05 — NeomycinD06AX04 — NeomycinS03AA01 — NeomycinA01AB08 — NeomycinA07AA01 — NeomycinS02AA07 — NeomycinB05CA09 — NeomycinS01AA03 — Neomycin
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
I16QD7X297
CAS number
1404-04-2

References

Synthesis Reference

Jaehoon Yu, Jongkook Lee, Miyun Kwon, Ae Pae, Hun Koh, "Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use." U.S. Patent US20050222055, issued October 06, 2005.

US20050222055
General References
  1. Lechevalier HA: The 25 years of neomycin. CRC Crit Rev Microbiol. 1975 May;3(4):359-97. [PubMed:1095304]
  2. Macdonald RH, Beck M: Neomycin: a review with particular reference to dermatological usage. Clin Exp Dermatol. 1983 May;8(3):249-58. doi: 10.1111/j.1365-2230.1983.tb01777.x. [PubMed:6224608]
  3. Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [PubMed:19438282]
  4. 49,50. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 63-). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  5. FDA Approved Drug Products: Neo-Fradin (Neomycin Sulfate) Oral Solution [Link]
  6. FDA Approved Drug Products: Casporyn Neomycin Sulfate, Polymixin B Sulfate, and Hydrocortisone Otic Drops [Link]
  7. FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension [Link]
  8. Cayman Chemical: Neomycin sulfate Safety Data Sheet [Link]
  9. Neomycin - LiverTox - NCBI Bookshelf [Link]
  10. Neomycin Opthalmic FDA Label [File]
  11. Neomycin Irrigation Solution FDA Label [File]
  12. Neomycin Otic FDA Label [File]
  13. Neomycin Tablet FDA Label [File]
KEGG Drug
D08260
KEGG Compound
C00384
PubChem Substance
46505525
RxNav
7299
ChEBI
7507
Therapeutic Targets Database
DAP000036
PharmGKB
PA450608
PDBe Ligand
CNY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Neomycin
AHFS Codes
  • 08:12.02 — Aminoglycosides
  • 84:04.04 — Antibiotics
FDA label
Download (169 KB)
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionSurgery, Colorectal1
4CompletedPreventionUrinary Tract Infection1
4CompletedTreatmentAllergies1
4CompletedTreatmentVaginal Inflammation1
4RecruitingBasic ScienceRabies Human1
4RecruitingTreatmentElective Colon Surgery1
3Unknown StatusTreatmentAcute / Bacterial Conjunctivitis1
3Unknown StatusTreatmentHordeolum1
2Active Not RecruitingTreatmentCrohn's Disease (CD)1
2CompletedTreatmentCrohn's Disease (CD)1

Pharmacoeconomics

Manufacturers
  • X gen pharmaceuticals inc
  • Pharmacia and upjohn co
  • Pfizer laboratories div pfizer inc
  • Bristol myers squibb co
  • Lannett co inc
  • Eli lilly and co
  • Oman pharmaceutical products co llc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
  • Akorn Inc.
  • Amend
  • Bausch & Lomb Inc.
  • Dispensing Solutions
  • Draxis Specialty Pharmaceuticals Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • X-Gen Pharmaceuticals
Dosage Forms
FormRouteStrength
KitOphthalmic; Topical
KitOphthalmic; Oral; Respiratory (inhalation); Topical
KitOphthalmic; Respiratory (inhalation); Topical
KitOral; Respiratory (inhalation); Topical
KitRespiratory (inhalation); Topical
KitIrrigation; Ophthalmic; Respiratory (inhalation); Topical
KitIrrigation; Ophthalmic; Topical
KitIrrigation; Oral; Respiratory (inhalation); Topical
KitIrrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical
KitOral; Topical
KitTopical
PowderTopical
OintmentTopical3.5 mg/1g
Solution / dropsOphthalmic0.5 %
Ointment50000 iu/100g
OintmentCutaneous12.5 mg
CreamTopical5 mg/0.9g
PowderTopical5000 IU/g
OintmentTopical5000 IU
OintmentTopical0.5 %
Ointment40000 iu/100g
PowderTopical75 iu/1g
PowderTopical750 iu/10g
PowderTopical7500 iu/100g
Solution / dropsAuricular (otic); Ophthalmic0.5 %
CreamTopical100 mg/100g
CreamTopical0.1 %
CreamTopical0.1 % w/w
CreamTopical0.12 % w/w
SyrupOral150000 UI
TabletOral25000 UI
TabletOral25000 IU
KitElectro-osmosis
CreamTopical5 MG/1MG
SuspensionOral50 mg/15mL
SuspensionAuricular (otic)1.538 mg
SuspensionOphthalmic3.5 mg
SuspensionOphthalmic1 mg
CreamTopical
SolutionAuricular (otic)
SuspensionTopical
KitOral
SolutionConjunctival; Ophthalmic1 mg
CreamTopical250 mg
OintmentTopical2.5 mg
CreamTopical1000 mg
CreamTopical250 mcg/1g
Solution / dropsAuricular (otic); Ophthalmic100 mg/100mL
Solution / dropsOphthalmic1 mg
Solution / dropsAuricular (otic); Ophthalmic0.1 %
OintmentOphthalmic; Topical
Tablet250 mg
CreamTopical0.04 g
Solution / dropsOphthalmic100 mg/100mL
Cream100 mg/100g
SolutionAuricular (otic); Topical1 mg
CreamTopical25 mg/100g
CreamTopical0.35 %
KitOphthalmic; Oral; Topical
CreamTopical1 %w/w
OintmentOphthalmic5 mg
CreamTopical500 mg/100g
SuspensionOral3 g/15mL
KitOphthalmic
StickTopical
CreamTopical0.02 %
OintmentTopical0.02 %
OintmentOphthalmic1 mg/1g
Suspension / dropsOphthalmic1 mg/1mL
OintmentOphthalmic3.5 mg/g
CreamTopical0.25 mg/g
LotionCutaneous0.25 mg/g
OintmentCutaneous0.25 mg/g
SolutionTopical0.25 mg/g
Ointment25000 iu/100g
Lozenge500 mcg
SolutionOral
TabletOral
OintmentTopical
SuspensionAuricular (otic); Ophthalmic
SolutionOral87.5 mg/5mL
LotionTopical
TabletOral350 mg
PowderOral49 %
LiquidAuricular (otic); Ophthalmic
CreamTopical50 mg/100g
PowderOral490000 IU/g
Powder; syrupOral3 g/15mL
PowderTopical25000 iu/100g
Powder, for solutionOral50 %
PowderOral71.5 g
SuspensionOral10 g/100mL
Powder, for solutionOral528.5 mg/g
IrrigantIrrigation
SolutionIrrigation
OintmentOphthalmic
SuspensionOphthalmic
Solution / dropsOphthalmic
Solution / dropsAuricular (otic)
Suspension / dropsAuricular (otic)
Suspension / dropsOphthalmic
PowderTopical1 g
PowderTopical500 mg
PowderNot applicable1 g/1g
TabletOral350 mg/1
TabletOral500 mg/1
Cream350 mg/100g
CreamTopical0.5 %
SolutionAuricular (otic); Ophthalmic
SolutionUrethral
Powder, for solutionOral715 mg/g
Cream250 mg/100g
CreamTopical0.5 % W/W
PowderOral50 % w/w
SuspensionOral1.5 g/15mL
CreamTopical350 mg/100g
SolutionOphthalmic1.3 mg
LiquidOphthalmic
SolutionConjunctival; Ophthalmic1.2 mg
GelTopical
SolutionConjunctival; Ophthalmic1.3 mg
Solution / dropsOphthalmic25 iu/1mL
OintmentAuricular (otic)35000 IU/10g
SolutionAuricular (otic)1 mg
SuspensionAuricular (otic)
Suspension / dropsAuricular (otic)10000 u
OintmentTopical3.5 mg/g
OintmentTopical3.5 mg/57g
GelTopical5 mg/100g
Cream500 mg/100g
OintmentRectal
SuppositoryRectal
PowderOral60 % W/W
CreamTopical1 % w/w
OintmentTopical
SolutionOphthalmic
OintmentTopical1 %
OintmentTopical2 %
PowderTopical5 %
PowderTopical99.5 %
PatchCutaneous
OintmentTopical500 IU/g
OintmentOphthalmic500 IU/g
PowderOral500 MG/G
SolutionOphthalmic1 mg
CreamTopical1 %
LotionTopical0.051 g
Ointment500 mg/100g
CreamTopical1 g
LozengeOral0.5 mg
OintmentTopical0.5 g
OintmentOphthalmic1 g
SuspensionConjunctival; Ophthalmic1 mg
OintmentConjunctival; Ophthalmic0.1 g
Solution / dropsOphthalmic25 mcg/1mL
Prices
Unit descriptionCostUnit
Neomycin Sulfate 500 mg tablet1.39USD tablet
Neomycin 500 mg tablet1.25USD tablet
Neomycin sulfate powder0.84USD g
Neo-fradin 125 mg/5 ml soln0.12USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709]
  4. Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [PubMed:6103875]
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
In prokaryotes, the 16S rRNA is essential for recognizing the 5' end of mRNA and hence positioning it correctly on the ribosome. The 16S rRNA has a characteristic secondary structure in which half of the nucleotides are base-paired. The 16S rRNA sequence has been highly conserved and is often used for evolutionary and species comparative analysis.
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Roy U, Nair D: Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology. 2007 Mar;16(2):253-61. Epub 2006 Nov 28. [PubMed:17131180]
  4. Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y: Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother. 2007 Dec;51(12):4401-9. Epub 2007 Sep 17. [PubMed:17875999]
  5. Brown JM, Cowley KD, Manninen KI, McNeil MM: Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic. Vet Microbiol. 2007 Nov 15;125(1-2):66-72. Epub 2007 May 6. [PubMed:17553640]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Gene Name
CASR
Uniprot ID
P41180
Uniprot Name
Extracellular calcium-sensing receptor
Molecular Weight
120672.385 Da
References
  1. Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007 Sep;293(3):F946-55. Epub 2007 May 30. [PubMed:17537980]

Drug created on June 13, 2005 07:24 / Updated on November 27, 2020 08:19

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates